Japanese pharmaceutical conglomerate Daiichi Sankyo remains committed to its plan to invest approximately one billion euros in expanding its development and production site in Pfaffenhofen, Bavaria.
Benoit Creveau, the company’s head in Germany, told the newspaper that the expansion is definitely not facing a halt. His statement comes against a backdrop where pharmaceutical companies like Eli Lilly and Boehringer Ingelheim have recently scaled back their investment plans in Germany, linking their decisions to criticisms of the federal government’s healthcare policies.
While Creveau acknowledged that the legislative draft for reform in the healthcare system was disappointing, he maintained that Germany continues to be a leading market for the pharmaceutical industry. He noted that alongside the healthcare policy framework, other factors significantly influenced the location decision, including established relationships with research institutions, the availability of qualified skilled workers, and reliable suppliers.
Daiichi Sankyo, which generates revenue of €11.5 billion, is the second-largest drug manufacturer in Japan. The Pfaffenhofen facility is the company’s largest operation outside of Japan, and this investment represents one of the highest in the group’s history.
